Status of circulatory level of secreted frizzled related protein 4 in metabolic syndrome
Keywords:
secreted frizzled related protein 4, metabolic syndrome, type II diabetes mellitus, adipocytokineAbstract
Background: Metabolic syndrome is a set of metabolic disorders and is considered as a predictor of cardiovascular risks. The expression of several specific genes and the related protein products also show their significance in pathophysiology of Metabolic Syndrome. Secreted Frizzled Related Protein 4 is a product of expression of SFRP4 genes. SFRP4 has been linked with inflammatory responses quite similar to the responses as in metabolic syndrome pathogenesis. Aim: The current study aimed to assess the circulatory level of Secreted Frizzled Related Protein 4 among metabolic syndrome individuals. Method: Estimation of SFRP4 was done by ELISA technique by using Human SFRP4 ELISA kit (Make- Bioassay Technology Laboratory, Cat no- E2327Hu, Zeijhang, China). Results: Mean concentration of serum SFRP4 in Metabolic Syndrome subjects (2.06 ± 1.39 ng/ml) was significantly higher than the mean concentration of healthy controls (1.28 ± 1.29 ng/ml) (p< 0.05 *). Conclusion: A significant correlation of serum SFRP4 level with Fasting blood glucose and HbA1c seen in the findings of this study puts on an extra contribution to consider this protein as a potential Biomarker for Type II Diabetes Mellitus.
Downloads
References
Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, et al. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol. 2013; 976810.
Anand K, Vidyasagar S, Lasrado I, Pandey GK, Amutha A, Ranjani H, Anjana RM, et al. Secreted frizzled-related protein 4 (SFRP4): a novel biomarker of beta-cell dysfunction and insulin resistance in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2016; 39: 147–8.
Bekaert M, Ouwens DM, Horbelt T, Velde FV, Fahlbusch P, Wiza DH, Nieuwenhove YV, et al. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity. 2016; 24: 2544–52.
Bergmann K, Sypniewska G. Secreted frizzled-related protein 4 (SFRP4) and fractalkine (CX3CL1)—Potential new biomarkers for beta-cell dysfunction and diabetes. Clin Biochem. 2014; 47: 529–32.
Brix JM, Krzizek EC, Hoebaus C, Ludvik B, Schernthaner GH et al. Secreted Frizzled Related Protein 4 (SFRP4) is elevated in patients with Diabetes Mellitus. Horm Metab Res. 2016; 48(5):345-8.
Guan H, Zhang Y, Gao S, et al. Differential patterns of secreted frizzled-related protein 4 (SFRP4) in adipocyte differentiation: Adipose depot specificity. Cell Physiol Biochem. 2018; 46: 2149–64.
Hennekens C, Lieberman E, Rubenstein M, et al. Lipid Modification in the Treatment and Prevention of Cardiovascular Diseases: New emerging clinical and public health challenges. In: Watson RR, ed. Handbook of Cholesterol. Urbana, IL: AOCS Press. 2016; 155-81. Chap 9.
Hennekens CH, Andreotti F. The leading avoidable cause of premature mortality in the world: the case for obesity. Am J Med. 2013; 126(2):97-8. PMID: 23331432.
Hoffmann MM, Werner C, Bohm M, Laufs U, Winkler K. Association of secreted frizzled-related protein 4 (SFRP4) with type 2 diabetes in patients with stable coronary artery disease. Cardiovasc Diabetol. 2014; 13:155.
Mahdi T, Hanzelmann S, Salehi A, Muhammed SJ, Reinbothe TM, Tang Y, Axelsson AS, et al. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab. 2012; 16: 625–33.
Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011; 18(8): 629–39.
Munro JM, Cotran RS. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest. 1988; 58: 249–61.
Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010; 329:454–57.
Reddy P, Lent-Schochet D, Ramakrishnan N, et al. Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes. Clin Chem Acta. 2019; 496: 35–44.
Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999; 340: 115–26.
Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer. J. Cardiovasc. Pharmacol. 2017; 22(4): 365-7.
Trayhurn P, Drevon CA, Eckel J. Secreted proteins from adipose tissue and skeletal muscle—Adipokines, myokines and adipose/- muscle cross-talk. Arch Physiol Biochem. 2011; 117: 47–56.
Wardana, I. M., Ardani, I. G. A. I., Aryani, L. N. A., Windiani, I. G. A. T., Adnyana, I. G. N. S., & Setiawati, Y. (2022). Other mental disorders ydt due to brain damage and dysfunction and physical disease in patients with anti-NMDA encephalitis: Case report. International Journal of Health & Medical Sciences, 5(4). https://doi.org/10.21744/ijhms.v5n4.1948
Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.